argenx Full Year 2024 Earnings: Beats Expectations

argenx (EBR:ARGX) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.25b (up 77% from FY 2023).
• Net income: US$833.0m (up from US$295.1m loss in FY 2023).
• Profit margin: 37% (up from net loss in FY 2023).
• EPS: US$13.92 (up from US$5.16 loss in FY 2023).

The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

ARGX Products In Clinical Trials

• Phase I: 2.

ARGX Post-Clinical Trial Products

• Pre-registration: 8.

All figures shown in the chart above are for the trailing 12 month (TTM) period

argenx Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 2.6%. Earnings per share (EPS) also surpassed analyst estimates significantly.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$1.90b (84% of total revenue). Notably, cost of sales worth US$1.21b amounted to 54% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$748.4m (71% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$850.9m. Explore how ARGX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe.

Performance of the market in Belgium.

The company's shares are up 3.2% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for argenx you should be aware of, and 1 of them is potentially serious.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.